King Wealth Management Group’s Acadia Pharmaceuticals ACAD Stock Holding History

King Wealth Management Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,000	Closed	-$206K	–	173
2021 Q1	$206K	Hold	8,000	–	–	0.05%	152
2020 Q4	$428K	Hold	8,000	–	–	0.1%	103
2020 Q3	$330K	Buy	8,000 +3,000	+60%	+$130K	0.09%	114
2020 Q2	$242K	Hold	5,000	–	–	0.07%	126
2020 Q1	$211K	Buy	+5,000	New	+$206K	0.09%	120

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

King Wealth Management Group's ACAD Position: Q2 2021 in Review

King Wealth Management Group sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 8,000 shares — an estimated $206K sold.

King Wealth Management Group first reported a position in ACAD in Q1 2020 and held it in 5 quarters. The position peaked at $428K in Q4 2020. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

King Wealth Management Group reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
King Wealth Management Group sold 8,000 Acadia Pharmaceuticals shares in Q2 2021, an estimated $206K.
King Wealth Management Group first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 5 quarters.
King Wealth Management Group's Acadia Pharmaceuticals position peaked at $428K in Q4 2020.
245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on King Wealth Management Group's 13F filing for Q2 2021, filed 12 Aug 2021.